NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 76 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2024. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $41,596 | -20.0% | 48,424 | 0.0% | 0.00% | – |
| Q3 2023 | $52,000 | -58.4% | 48,424 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $125,000 | -38.1% | 48,424 | -2.0% | 0.00% | 0.0% |
| Q1 2023 | $202,000 | -18.5% | 49,424 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $248,000 | -11.1% | 49,424 | +170.4% | 0.00% | 0.0% |
| Q1 2022 | $279,000 | -49.3% | 18,277 | -41.1% | 0.00% | -50.0% |
| Q4 2021 | $550,000 | -15.6% | 31,032 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $652,000 | – | 31,032 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
| Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
| Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
| Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
| Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
| Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
| Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
| Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
| Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |